
RallyBio In-Licensing Potential First-In-Class Antibody from Sanofi.
RallyBio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, a preclinical potentially first-in-class antibody.